Blair William & Co. IL Makes New $1.43 Million Investment in Neurogene Inc. (NASDAQ:NGNE)

Blair William & Co. IL purchased a new stake in Neurogene Inc. (NASDAQ:NGNE - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 62,640 shares of the company's stock, valued at approximately $1,432,000. Blair William & Co. IL owned 0.42% of Neurogene as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. PNC Financial Services Group Inc. bought a new position in Neurogene in the 4th quarter worth about $71,000. China Universal Asset Management Co. Ltd. bought a new stake in Neurogene during the 4th quarter valued at $72,000. BNP Paribas Financial Markets boosted its position in Neurogene by 192.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company's stock worth $91,000 after acquiring an additional 1,429 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Neurogene by 72.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 10,290 shares of the company's stock worth $239,000 after purchasing an additional 4,334 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in shares of Neurogene during the third quarter valued at $254,000. Institutional investors own 52.37% of the company's stock.

Analyst Upgrades and Downgrades

NGNE has been the subject of a number of recent analyst reports. William Blair reiterated an "outperform" rating on shares of Neurogene in a research report on Tuesday, March 25th. HC Wainwright dropped their price objective on Neurogene from $55.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 25th. Finally, Robert W. Baird set a $38.00 target price on Neurogene in a research note on Tuesday, March 25th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Neurogene has an average rating of "Buy" and an average price target of $53.00.

Remove Ads

Neurogene Price Performance

NASDAQ NGNE traded down $0.93 on Monday, hitting $7.86. 545,787 shares of the company were exchanged, compared to its average volume of 215,378. Neurogene Inc. has a twelve month low of $7.67 and a twelve month high of $74.49. The firm has a market capitalization of $117.35 million, a P/E ratio of -1.84 and a beta of 1.46. The company's 50 day moving average price is $16.14 and its 200-day moving average price is $27.35.

Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.05. The firm had revenue of $0.93 million for the quarter. As a group, equities analysts expect that Neurogene Inc. will post -4.27 EPS for the current year.

Insider Transactions at Neurogene

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the transaction, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This represents a 5.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.92% of the stock is currently owned by insiders.

Neurogene Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.